Modality
Fusion Protein
MOA
IL-13i
Target
RET
Pathway
Fibrosis
Wilms
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
~Oct 2019
→ ~Jan 2021
Phase 2
Apr 2021
→ Oct 2025
Phase 2Current
NCT08159623
1,928 pts·Wilms
2021-04→2025-10·Recruiting
1,928 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-10-235mo agoPh3 Readout· Wilms
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P2/3
Recruit…
Catalysts
Ph3 Readout
2025-10-23 · 5mo ago
Wilms
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08159623 | Phase 2/3 | Wilms | Recruiting | 1928 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-5389 | Roche | Preclinical | RET | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 |